Advanced search
Publication Cover
Current Medical Research and Opinion Volume 23, 2007 - Issue 12
Submit an article Journal homepage
598
Views
55
CrossRef citations to date
0
Altmetric
Original Article

Rivastigmine exposure provided by a transdermal patch versus capsules

François Mercier Novartis Pharma AG, Basel, SwitzerlandCorrespondence[email protected]
,
Gilbert Lefèvre Novartis Pharma AG, Basel, Switzerland
,
Hsun-Lun Aaron Huang Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Heinz Schmidli Novartis Pharma AG, Basel, Switzerland
,
Billy Amzal Novartis Pharma AG, Basel, Switzerland
&
Silke Appel-Dingemanse Novartis Pharma AG, Basel, Switzerland
Pages 3199-3204 | Accepted 21 Oct 2007, Published online: 13 Nov 2007

Citations (55)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Seok Kyu Yoon, Kyun-Seop Bae, Dong Hyun Hong, Seong Su Kim, Young Kweon Choi & Hyeong-Seok Lim. (2020) Pharmacokinetic Evaluation by Modeling and Simulation Analysis of a Donepezil Patch Formulation in Healthy Male Volunteers. Drug Design, Development and Therapy 14, pages 1729-1737.
Read now
Andrea Haake, Kevin Nguyen, Lauren Friedman, Binu Chakkamparambil & George T Grossberg. (2020) An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Drug Safety 19:2, pages 147-157.
Read now
Nagaendran Kandiah, Ming-Chyi Pai, Vorapun Senanarong, Irene Looi, Encarnita Ampil, Kyung Won Park, Ananda Krishna Karanam & Stephen Christopher. (2017) Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia. Clinical Interventions in Aging 12, pages 697-707.
Read now
Rachel A. Nieto, William James Deardorff & George T. Grossberg. (2016) Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer’s disease. Expert Opinion on Pharmacotherapy 17:6, pages 861-870.
Read now
Yo Han Kim, Hee Youn Choi, Hyeong-Seok Lim, Shi Hyang Lee, Hae Sun Jeon, Donghyun Hong, Seong Su Kim, Young Kweon Choi & Kyun-Seop Bae. (2015) Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. Drug Design, Development and Therapy 9, pages 1419-1426.
Read now
Takemi Kimura & Junichi Takamatsu. (2013) Two cases of Alzheimer’s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil. Neuropsychiatric Disease and Treatment 9, pages 49-53.
Read now
José Luis Molinuevo & Francisco Javier Arranz. (2012) Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer’s disease. Expert Review of Neurotherapeutics 12:1, pages 31-37.
Read now
Taher Darreh-Shori & Vesna Jelic. (2010) Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert Opinion on Drug Safety 9:1, pages 167-176.
Read now
Shilpa Chitnis & Jayaraman Rao. (2009) Rivastigmine in Parkinson's disease dementia. Expert Opinion on Drug Metabolism & Toxicology 5:8, pages 941-955.
Read now
Andreas Wentrup, Wolfgang H Oertel & Richard Dodel. (2008) Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease. Drug Design, Development and Therapy 2, pages 245-254.
Read now
Bengt Winblad & João Carlos Machado. (2008) Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opinion on Drug Delivery 5:12, pages 1377-1386.
Read now
Stefania Lalli & Alberto Albanese. (2008) Rivastigmine in Parkinson’s disease dementia. Expert Review of Neurotherapeutics 8:8, pages 1181-1188.
Read now

Articles from other publishers (43)

Maha A. MarzoukAsmaa M. ElbakryRawia M. KhalilAreej W. Zahran. (2022) Carvedilol- loaded Transdermal Ethosomal gel: Characterization, ex vivo/in vivo Evaluation. Research Journal of Pharmacy and Technology, pages 4017-4023.
Crossref
Gabriella Marucci, Michela Buccioni, Diego Dal Ben, Catia Lambertucci, Rosaria Volpini & Francesco Amenta. (2021) Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology 190, pages 108352.
Crossref
Kevin Nguyen, Heidi Hoffman, Binu Chakkamparambil & George T Grossberg. (2021) Evaluation of rivastigmine in Alzheimer's disease. Neurodegenerative Disease Management 11:1, pages 35-48.
Crossref
Alberto J. Espay, Luca Marsili, Abhimanyu Mahajan, Andrea Sturchio, Rashidkhan Pathan, Andrea Pilotto, Damodaran S. Elango, Nicole Pezous, Mario Masellis & Baltazar Gomez‐Mancilla. (2020) Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. Annals of Neurology 89:1, pages 91-98.
Crossref
Anne J. Keurentjes & Howard I. Maibach. (2019) Percutaneous penetration of drugs applied in transdermal delivery systems: an in vivo based approach for evaluating computer generated penetration models. Regulatory Toxicology and Pharmacology 108, pages 104428.
Crossref
Ping-Song Chou, Kai-Ming Jhang, Ling-Chun Huang, Wen-Fu Wang & Yuan-Han Yang. (2019) Skinfold thickness for rivastigmine patch application in Alzheimer’s disease. Psychopharmacology 236:4, pages 1255-1260.
Crossref
Yumiko Kutoku & Masahito Mihara. (2018) Drug Treatments of Dementia認知症の薬物療法. The Japanese Journal of Rehabilitation Medicine 55:8, pages 643-647.
Crossref
Rita Khoury, Jayashree Rajamanickam & George T. Grossberg. (2018) An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine. Therapeutic Advances in Drug Safety 9:3, pages 171-178.
Crossref
Alice Simon, Maria Inês Amaro, Anne Marie Healy, Lucio Mendes Cabral & Valeria Pereira de Sousa. (2016) Comparative evaluation of rivastigmine permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with in vivo-in vitro correlation. International Journal of Pharmaceutics 512:1, pages 234-241.
Crossref
Nuggehally R. Srinivas. (2016) Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. Clinical Neuropharmacology 39:4, pages 169-177.
Crossref
Grazia D'Onofrio, Daniele Sancarlo, Filomena Addante, Filomena Ciccone, Leandro Cascavilla, Francesco Paris, Anna Chiara Elia, Claudia Nuzzaci, Michele Picoco, Antonio Greco, Francesco Panza & Alberto Pilotto. (2015) A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 30:9, pages 965-975.
Crossref
E. E. Vasenina & O. S. Levin. (2015) Characteristics of the clinical picture and treatment of moderate or severe Alzheimer’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 115:6. Vyp. 2, pages 17.
Crossref
Martin R. Farlow, George T. Grossberg, Carl H. Sadowsky, Xiangyi Meng & Monique Somogyi. (2013) A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia. CNS Neuroscience & Therapeutics 19:10, pages 745-752.
Crossref
Haijun Tian, Safiya Abouzaid, Wei Chen, Kristijan H. Kahler & Edward Kim. (2013) Patient Adherence to Transdermal Rivastigmine After Switching From Oral Donepezil. Alzheimer Disease & Associated Disorders 27:2, pages 182-186.
Crossref
Wantida Chaiyana, Jan Schripsema, Kornkanok Ingkaninan & Siriporn Okonogi. (2013) 3′-R/S-Hydroxyvoacamine, a potent acetylcholinesterase inhibitor from Tabernaemontana divaricata. Phytomedicine 20:6, pages 543-548.
Crossref
Muriel Noetzli & Chin B. Eap. (2013) Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease. Clinical Pharmacokinetics 52:4, pages 225-241.
Crossref
Miriam Isaac & Carl Holvey. (2012) Transdermal patches: the emerging mode of drug delivery system in psychiatry. Therapeutic Advances in Psychopharmacology 2:6, pages 255-263.
Crossref
Jacquelyn Levin & Howard Maibach. (2012) Interindividual Variation in Transdermal and Oral Drug Deliveries. Journal of Pharmaceutical Sciences 101:11, pages 4293-4307.
Crossref
Peter PREGELJ. (2012) Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions. Psychogeriatrics 12:3, pages 165-171.
Crossref
Wantida Chaiyana & Siriporn Okonogi. (2012) Inhibition of cholinesterase by essential oil from food plant. Phytomedicine 19:8-9, pages 836-839.
Crossref
So Hee Nam, Jae-Hwan Jeong, Xiangguo Che, Kyung-Eun Lim, Hyemi Nam, Jong-Sang Park & Je-Yong Choi. (2012) Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model. Bone 50:1, pages 149-155.
Crossref
Martin R. Farlow, George T. Grossberg, Xiangyi Meng, Jason Olin & Monique Somogyi. (2010) Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry 26:12, pages 1236-1243.
Crossref
K. Articus, M. Baier, F. Tracik, F. Kühn, U. W. Preuß & A. Kurz. (2011) A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer’s disease. International Journal of Clinical Practice 65:7, pages 790-796.
Crossref
Wantida Chaiyana, Kiattisak Saeio, Wim E. Hennink & Siriporn Okonogi. (2011) Corrigendum to “Characterization of potent anticholinesterase plant oil based microemulsion” [Int. J. Pharm. 401 (2010) 32–40]. International Journal of Pharmaceutics 414:1-2, pages 333-334.
Crossref
Sohita Dhillon. (2011) Rivastigmine Transdermal Patch. Drugs 71:9, pages 1209-1231.
Crossref
Balázs Nagy, Alan Brennan, Ágnes Brandtmüller, Simu K. Thomas, Sean D. Sullivan & Ron Akehurst. (2011) Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. International Journal of Geriatric Psychiatry 26:5, pages 483-494.
Crossref
Gary Small & Roger Bullock. (2010) Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. Alzheimer's & Dementia 7:2, pages 177-184.
Crossref
Wantida Chaiyana, Kiattisak Saeio, Wim E. Hennink & Siriporn Okonogi. (2010) Characterization of potent anticholinesterase plant oil based microemulsion. International Journal of Pharmaceutics 401:1-2, pages 32-40.
Crossref
Ejaz Nazir & Muhammad Mushtaq. (2010) A prospective study on the use of rivastigmine transdermal patch in Alzheimer's dementia in a routine clinical setting. Dementia & Neuropsychologia 4:3, pages 245-249.
Crossref
Murat Emre, Roberto Bernabei, Rafael Blesa, Roger Bullock, Luis Cunha, Hugo Daniëls, Edward Dziadulewicz, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, Oleg Levin, James Lindesay, Pablo Martínez‐Lage, Andreas Monsch, Magda Tsolaki & Teus Van Laar. (2010) Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. CNS Neuroscience & Therapeutics 16:4, pages 246-253.
Crossref
G. T. Grossberg, C. Sadowsky & J. T. Olin. (2010) Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease. International Journal of Clinical Practice 64:5, pages 651-660.
Crossref
C. Sadowsky, J.A. Davila Perez, R.W. Bouchard, I. Goodman & S. Tekin. (2010) Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch. CNS Neuroscience & Therapeutics 16:1, pages 51-60.
Crossref
C. H. Sadowsky, M. R. Farlow, X. Meng & J. T. Olin. (2009) Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. International Journal of Clinical Practice 64:2, pages 188-193.
Crossref
J.L.C.M. Dorne, J.L.C.M. Dorne, L.R. Bordajandi, B. Amzal, P. Ferrari & P. Verger. (2009) Combining analytical techniques, exposure assessment and biological effects for risk assessment of chemicals in food. TrAC Trends in Analytical Chemistry 28:6, pages 695-707.
Crossref
Krista L. LanctôtRyan D. Rajaram & Nathan Herrmann. (2009) Review: Therapy for Alzheimer's disease: how effective are current treatments?. Therapeutic Advances in Neurological Disorders 2:3, pages 163-180.
Crossref
A. Kurz, M. Farlow & G. Lefèvre. (2009) Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review. International Journal of Clinical Practice 63:5, pages 799-805.
Crossref
Gilbert Lefèvre, Monika Büche, Greg Sedek, Steve Maton, Albert Enz, Ulrike Lorch, Cyriaque Sagan & Silke Appel-Dingemanse. (2009) Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch. The Journal of Clinical Pharmacology 49:4, pages 430-443.
Crossref
George Grossberg, Carl Sadowsky, Hans Förstl, Lutz Frölich, Jennifer Nagel, Sibel Tekin, Stefanie Zechner, Jacqueline Ros & Jean-Marc Orgogozo. (2009) Safety and Tolerability of the Rivastigmine Patch. Alzheimer Disease & Associated Disorders 23:2, pages 158-164.
Crossref
Sara Farahmand & Howard I. Maibach. (2009) Transdermal drug pharmacokinetics in man: Interindividual variability and partial prediction. International Journal of Pharmaceutics 367:1-2, pages 1-15.
Crossref
M. A. Cenci & P. Odin. 2009. Cortico-Subcortical Dynamics in Parkinson¿s Disease. Cortico-Subcortical Dynamics in Parkinson¿s Disease 1 26 .
. (2008) Current World Literature. Current Opinion in Psychiatry 21:6, pages 651-659.
Crossref
Jerson Laks & Eliasz Engelhardt. (2008) Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence?. Current Opinion in Psychiatry 21:6, pages 562-567.
Crossref
&NA;. (2008) Rivastigmine transdermal patch: a guide to its use in dementia of the Alzheimer??s type. Drugs & Therapy Perspectives 24:4, pages 5-8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.